Equillium reports lower-than-expected Q4 net loss

Reuters

1 hour ago

Equillium reports lower-than-expected Q4 net loss

Overview

US biotechnology firm's fiscal Q4 net loss narrowed, beating analyst expectations

Outlook

Equillium plans to initiate Phase 1 EQ504 study in mid-2026, with data in late 2026
Company expects cash and equivalents, inclusive of the March 2026 financing, to fund operations into 2029

Result Drivers

R&D SPENDING DECLINE - Co said lower R&D expenses were primarily due to the wind down of clinical studies in 2025

Company press release: ID:nGNXpSrM4

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS	Beat	-$0.04	-$0.06 (4 Analysts)
Q4 Net Income	Beat	-$3.78 mln	-$5.06 mln (4 Analysts)
Q4 Operating Income	Beat	-$3.96 mln	-$4.73 mln (4 Analysts)
Q4 Operating Expenses		$3.96 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Equillium Inc is $4.50, about 130.8% above its March 24 closing price of $1.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622002719"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622002719\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622002719?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 04:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622002719","market":"us","top_or_hot":-1,"title":"Equillium reports lower-than-expected Q4 net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Equillium reports lower-than-expected Q4 net loss</title></head><body><p><span>Overview</span></p><ul><li><p>US biotechnology firm's fiscal Q4 net loss narrowed, beating analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Equillium plans to initiate Phase 1 EQ504 study in mid-2026, with data in late 2026</p></li><li><p>Company expects cash and equivalents, inclusive of the March 2026 financing, to fund operations into 2029</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D SPENDING DECLINE - Co said lower R&amp;D expenses were primarily due to the wind down of clinical studies in 2025</p></li></ul><p>Company press release: <span>ID:nGNXpSrM4</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td><p>Beat</p></td><td><p>-$0.04</p></td><td><p>-$0.06 (4 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td><p>Beat</p></td><td><p>-$3.78 mln</p></td><td><p>-$5.06 mln (4 Analysts)</p></td></tr><tr><td><p>Q4 Operating Income</p></td><td><p>Beat</p></td><td><p>-$3.96 mln</p></td><td><p>-$4.73 mln (4 Analysts)</p></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$3.96 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Equillium Inc is $4.50, about 130.8% above its March 24 closing price of $1.95</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Equillium reports lower-than-expected Q4 net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEquillium reports lower-than-expected Q4 net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 04:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Equillium reports lower-than-expected Q4 net loss</title></head><body><p><span>Overview</span></p><ul><li><p>US biotechnology firm's fiscal Q4 net loss narrowed, beating analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Equillium plans to initiate Phase 1 EQ504 study in mid-2026, with data in late 2026</p></li><li><p>Company expects cash and equivalents, inclusive of the March 2026 financing, to fund operations into 2029</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D SPENDING DECLINE - Co said lower R&amp;D expenses were primarily due to the wind down of clinical studies in 2025</p></li></ul><p>Company press release: <span>ID:nGNXpSrM4</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td><p>Beat</p></td><td><p>-$0.04</p></td><td><p>-$0.06 (4 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td><p>Beat</p></td><td><p>-$3.78 mln</p></td><td><p>-$5.06 mln (4 Analysts)</p></td></tr><tr><td><p>Q4 Operating Income</p></td><td><p>Beat</p></td><td><p>-$3.96 mln</p></td><td><p>-$4.73 mln (4 Analysts)</p></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$3.96 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Equillium Inc is $4.50, about 130.8% above its March 24 closing price of $1.95</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL1N40D13Q:1","article_id":"2622002719","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622002719","pubTimestamp":1774471596,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Equillium reports lower-than-expected Q4 net lossOverviewUS biotechnology firm's fiscal Q4 net loss narrowed, beating analyst expectationsOutlookEquillium plans to initiate Phase 1 EQ504 study in mid-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4568":"美国抗疫概念","EQ":"Equillium Inc."},"translate_title":"Equillium报告第四季度净亏损低于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQ":0.9},"content_text":"Equillium reports lower-than-expected Q4 net lossOverviewUS biotechnology firm's fiscal Q4 net loss narrowed, beating analyst expectationsOutlookEquillium plans to initiate Phase 1 EQ504 study in mid-2026, with data in late 2026Company expects cash and equivalents, inclusive of the March 2026 financing, to fund operations into 2029Result DriversR&D SPENDING DECLINE - Co said lower R&D expenses were primarily due to the wind down of clinical studies in 2025Company press release: ID:nGNXpSrM4Key DetailsMetricBeat/MissActualConsensus EstimateQ4 EPSBeat-$0.04-$0.06 (4 Analysts)Q4 Net IncomeBeat-$3.78 mln-$5.06 mln (4 Analysts)Q4 Operating IncomeBeat-$3.96 mln-$4.73 mln (4 Analysts)Q4 Operating Expenses$3.96 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Equillium Inc is $4.50, about 130.8% above its March 24 closing price of $1.95For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}